You have no items in your shopping cart.
c-Ret
Catalog No. | Inhibitor Name | c-RET | Other |
---|---|---|---|
A10250 | Regorafenib | **** | Raf-1,VEGFR2,Kit |
A10715 | Danusertib | ** | Aurora A,Abl,TrkA |
A11180 | TG101209 | *** | JAK2,FLT3,JAK3 |
A13832 | RPI-1 | * |
Notes:
1.Hover mouse over " " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
Catalog No. | Product Name | Application | Product Information |
---|---|---|---|
A10250 SALE |
Regorafenib (BAY 73-4506) |
VEGFR inhibitor |
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
|
A10715 SALE |
Danusertib (PHA-739358) |
Aurora inhibitor |
Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2
|
A11180 |
TG101209 |
JAK2 inhibitor |
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. |
A13832 SALE |
RPI-1 |
Ret kinase inhibitor |
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
|
A15218 |
Regorafenib monohydrate |
Tyrosine kinase inhibitor |
Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
|